Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England

New insights into the burden and costs of multiple sclerosis in Europe

(2017) Gisela Kobelt et al.   Multiple Sclerosis Journal

Adjusting for Treatment Switching in the Relapsing-Remitting Multiple Sclerosis Clarity Trial and the Clarity Extension Study

(2017) H Bell Gorrod et al.   VALUE IN HEALTH

Impact Of Non-Randomised Drop-Out On Treatment Switching Adjustment In The Relapsing-Remitting Multiple Sclerosis Clarity Trial And The Clarity Extension Study

(2017) H Bell Gorrod et al.   VALUE IN HEALTH

New insights into the burden and costs of multiple sclerosis in Europe

(2017) Gisela Kobelt et al.   Multiple Sclerosis Journal

Breast Cancer in Young Women

(2016) Justin G. Trogdon et al.   AMERICAN JOURNAL OF PREVENTIVE MEDICINE

Alemtuzumab for multiple sclerosis: Long term follow-up in a multi-centre cohort

(2016) MD Willis et al.   Multiple Sclerosis Journal

Health Utilities for Multiple Sclerosis

(2016) Annie Hawton et al.   VALUE IN HEALTH

Alemtuzumab for multiple sclerosis: Long term follow-up in a multi-centre cohort

(2016) MD Willis et al.   Multiple Sclerosis Journal

Effectiveness and cost-effectiveness of interferon beta and glatiramer acetate in the UK Multiple Sclerosis Risk Sharing Scheme at 6 years: a clinical cohort study with natural history comparator

(2015) Jacqueline Palace et al.   LANCET NEUROLOGY

Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy

(2014) O. Tuohy et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

UK multiple sclerosis risk-sharing scheme: a new natural history dataset and an improved Markov model

(2014) Jacqueline Palace et al.   BMJ Open

A forgotten aspect of the NICE reference case: an observational study of the health related quality of life impact on caregivers of people with multiple sclerosis

(2013) Sarah Acaster et al.   BMC HEALTH SERVICES RESEARCH

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

(2012) Jeffrey A Cohen et al.   LANCET

Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from five European countries

(2012) Korinna Karampampa et al.   Multiple Sclerosis Journal

Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis

(2011) Gavin Giovannoni et al.   LANCET NEUROLOGY

New perspectives in the natural history of multiple sclerosis

(2010) H. Tremlett et al.   NEUROLOGY

A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis

(2010) Gavin Giovannoni et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cost-Effectiveness Analyses of Natalizumab (Tysabri®) Compared with Other Disease-Modifying Therapies for People with Highly Active Relapsing-Remitting Multiple Sclerosis in the UK

(2009) Ray Gani et al.   PHARMACOECONOMICS

Genetics and pathogenesis of multiple sclerosis

(2009) R.L. Zuvich et al.   SEMINARS IN IMMUNOLOGY

Cost-Effectiveness of Disease-Modifying Therapies in the Management of Multiple Sclerosis for the Medicare Population

(2009) Paul Tappenden et al.   VALUE IN HEALTH

Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis

(2008)   NEW ENGLAND JOURNAL OF MEDICINE